26166-39-2
26166-39-2 結構式
基本信息
ascochlorin
Ilicicolin D
Ll-Z 1272 gamma
Antibiotics LL-Z 1272g
Antibiotic ll-Z1272 gamma
LL-Z 1272 gaMMa, Ilicicolin D
beta-Resorcylaldehyde, 5-chloro-6-methyl-3-(3-methyl-5-(1,2,6-trimethyl-3-oxocyclohexyl)-2,4-pentadienyl)-, (E,E)-
5-Chloro-2,4-dihydroxy-6-methyl-3-[(2E,4Z)-3-methyl-5-(1,2,6-trimethyl-3-oxocyclohexyl)penta-2,4-dienyl]benzaldehyde
3-Chloro-4,6-dihydroxy-2-methyl-5-[(2E,4E)-3-methyl-5-[(1R)-1β,2β,6β-trimethyl-3-oxocyclohexyl]-2,4-pentadienyl]benzaldehyde
物理化學性質
安全數(shù)據(jù)
常見問題列表
|
STAT3
|
Apoptosis
|
Ascochlorin (Ilicicolin D) (10-50 μM; 24-72 hours) inhibits the viability of HepG2, HCCLM3 and Huh7 cells in a time and dose dependent manner.
Ascochlorin (50 μM; 48 hours) induces apoptosis in HCC cells.
Ascochlorin (1-50 μM) significantly suppresses the production of nitric oxide (NO) and prostaglandin E2 (PGE2) and decreases the gene expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) in a dose-dependent manner. Ascochlorin inhibits the mRNA expression and the protein secretion of interleukin (IL)-1β and IL-6 but not tumor necrosis factor (TNF)-α in LPS-stimulated RAW 264.7 macrophage cells. Ascochlorin suppresses nuclear translocation and DNA binding affinity of nuclear factor-κB (NF-κB). Ascochlorin down-regulates phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) and p-p38.
Cell Viability Assay
| Cell Line: | HepG2, HCCLM3, Huh7 cells |
| Concentration: | 10, 25, 50 μM |
| Incubation Time: | 24, 48, 72 hours |
| Result: | Inhibit the viability of three different HCC cell lines tested (HepG2, HCCLM3 and Huh7) in a time and dose dependent manner. |
Western Blot Analysis
| Cell Line: | HepG2 cells |
| Concentration: | 50 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited expression of the cell cycle regulator protein cyclin D1, the anti-apoptotic proteins Bcl-2, Mcl-1, survivin and XIAP, and the invasive gene product MMP-9. |
Ascochlorin (Ilicicolin D) (2.5-5 mg/kg; i.p.; day 0, 1, 2, 3, 13, 15, 17, 20, 22, 24, 27, 29 and 31) inhibits tumor growth in an orthotopic HCC mouse model.
| Animal Model: | Eight week-old athymic balb/c nude female mice (HCCLM3-Luc2 tumors) |
| Dosage: | 2.5 mg/kg, 5 mg/kg |
| Administration: | I.p.; day 0, 1, 2, 3, 13, 15, 17, 20, 22, 24, 27, 29 and 31 |
| Result: | Induced significant inhibition of tumor growth. |